Oksana Polesskaya1, Christopher Wong2, Luis Lebron3, Jeffrey M Chamberlain3, Harris A Gelbard4, Val Goodfellow5, Minsoo Kim6, John L Daiss7, Stephen Dewhurst8. 1. Department of Microbiology and Immunology, University of Rochester Medical Center, Rochester, 14642 NY, USA. Electronic address: oksana_polesskaya@urmc.rochester.edu. 2. Department of Microbiology and Immunology, University of Rochester Medical Center, Rochester, 14642 NY, USA; Carleton College, 1N College Street, Northfield, MN 55057, USA. 3. Department of Microbiology and Immunology, University of Rochester Medical Center, Rochester, 14642 NY, USA. 4. Department of Microbiology and Immunology, University of Rochester Medical Center, Rochester, 14642 NY, USA; Center for Neural Development and Disease, and Departments of Pediatrics and Neurology, University of Rochester Medical Center, Rochester 14642, NY, USA. 5. Califia Bio Inc., 11575 Sorrento Valley Road, San Diego, CA, USA. 6. Department of Microbiology and Immunology, University of Rochester Medical Center, Rochester, 14642 NY, USA; David H. Smith Center for Vaccine Biology and Immunology, University of Rochester Medical Center, Rochester, 14642 NY, USA. 7. Department of Microbiology and Immunology, University of Rochester Medical Center, Rochester, 14642 NY, USA; Center for Musculoskeletal Research, and Department of Orthopaedics, University of Rochester Medical Center, 601 Elmwood Avenue, Box 672, Rochester 14642, NY, USA. 8. Department of Microbiology and Immunology, University of Rochester Medical Center, Rochester, 14642 NY, USA. Electronic address: stephen_dewhurst@urmc.rochester.edu.
Abstract
INTRODUCTION: Mixed lineage kinase 3 (MLK3) is part of the intracellular regulatory system that connects extracellular cytokine or mitogen signals received through G-protein coupled receptors to changes in gene expression. MLK3 activation stimulates motility of epithelial cells and epithelial-derived tumor cells, but its role in mediating the migration of other cell types remains unknown. Since neutrophils play a crucial role in innate immunity and contribute to the pathogenesis of several diseases, we therefore examined whether MLK3 might regulate the motility of mouse neutrophils responding to a chemotactic stimulus, the model bacterial chemoattractant fMLP. METHODS: The expression of Mlk3 in mouse neutrophils was determined by immunocytochemistry and by RT-PCR. In vitro chemotaxis in a gradient of fMLP, fMLP-stimulated random motility, fMLP-stimulated F-actin formation were measured by direct microscopic observation using neutrophils pre-treated with a novel small molecule inhibitor of MLK3 (URMC099) or neutrophils obtained from Mlk3-/- mice. In vivo effects of MLK3 inhibition were measured by counting the fMLP-induced accumulation of neutrophils in the peritoneum following pre-treatment with URMC099 in wild-type C57Bl/6 or mutant Mlk3-/- mice. RESULTS: The expression of Mlk3 mRNA and protein was observed in neutrophils purified from wild-type C57Bl/6 mice but not in neutrophils from mutant Mlk3-/- mice. Chemotaxis by wild-type neutrophils induced by a gradient of fMLP was reduced by pre-treatment with URMC099. Neutrophils from C57Bl/6 mice pretreated with URMC099 and neutrophils from Mlk3-/- mice moved far less upon fMLP-stimulation and did not form F-actin as readily as untreated neutrophils from C57Bl/6 controls. In vivo recruitment of neutrophils into the peritoneum by fMLP was significantly reduced in wild-type mice treated with URMC099, as well as in untreated Mlk3-/- mice-thereby confirming the role of MLK3 in neutrophil migration. CONCLUSIONS: Mlk3 mRNA is expressed in murine neutrophils. Genetic or pharmacologic inhibition of MLK3 blocks fMLP-mediated motility of neutrophils both in vitro and in vivo, suggesting that MLK3 may be a therapeutic target in human diseases characterized by exuberant neutrophil migration.
INTRODUCTION:Mixed lineage kinase 3 (MLK3) is part of the intracellular regulatory system that connects extracellular cytokine or mitogen signals received through G-protein coupled receptors to changes in gene expression. MLK3 activation stimulates motility of epithelial cells and epithelial-derived tumor cells, but its role in mediating the migration of other cell types remains unknown. Since neutrophils play a crucial role in innate immunity and contribute to the pathogenesis of several diseases, we therefore examined whether MLK3 might regulate the motility of mouse neutrophils responding to a chemotactic stimulus, the model bacterial chemoattractant fMLP. METHODS: The expression of Mlk3 in mouse neutrophils was determined by immunocytochemistry and by RT-PCR. In vitro chemotaxis in a gradient of fMLP, fMLP-stimulated random motility, fMLP-stimulated F-actin formation were measured by direct microscopic observation using neutrophils pre-treated with a novel small molecule inhibitor of MLK3 (URMC099) or neutrophils obtained from Mlk3-/- mice. In vivo effects of MLK3 inhibition were measured by counting the fMLP-induced accumulation of neutrophils in the peritoneum following pre-treatment with URMC099 in wild-type C57Bl/6 or mutant Mlk3-/- mice. RESULTS: The expression of Mlk3 mRNA and protein was observed in neutrophils purified from wild-type C57Bl/6 mice but not in neutrophils from mutant Mlk3-/- mice. Chemotaxis by wild-type neutrophils induced by a gradient of fMLP was reduced by pre-treatment with URMC099. Neutrophils from C57Bl/6 mice pretreated with URMC099 and neutrophils from Mlk3-/- mice moved far less upon fMLP-stimulation and did not form F-actin as readily as untreated neutrophils from C57Bl/6 controls. In vivo recruitment of neutrophils into the peritoneum by fMLP was significantly reduced in wild-type mice treated with URMC099, as well as in untreated Mlk3-/- mice-thereby confirming the role of MLK3 in neutrophil migration. CONCLUSIONS:Mlk3 mRNA is expressed in murine neutrophils. Genetic or pharmacologic inhibition of MLK3 blocks fMLP-mediated motility of neutrophils both in vitro and in vivo, suggesting that MLK3 may be a therapeutic target in human diseases characterized by exuberant neutrophil migration.
Authors: Val S Goodfellow; Colin J Loweth; Satheesh B Ravula; Torsten Wiemann; Thong Nguyen; Yang Xu; Daniel E Todd; David Sheppard; Scott Pollack; Oksana Polesskaya; Daniel F Marker; Stephen Dewhurst; Harris A Gelbard Journal: J Med Chem Date: 2013-10-03 Impact factor: 7.446
Authors: Hua Zhang; Wei Wu; Yan Du; Sarah J Santos; Susan E Conrad; Jack T Watson; Nicholas Grammatikakis; Kathleen A Gallo Journal: J Biol Chem Date: 2004-03-04 Impact factor: 5.157
Authors: Daniel F Marker; Marie-Ève Tremblay; Jenna M Puccini; Justin Barbieri; Mary A Gantz Marker; Colin J Loweth; E Chris Muly; Shao-Ming Lu; Val S Goodfellow; Stephen Dewhurst; Harris A Gelbard Journal: J Neurosci Date: 2013-06-12 Impact factor: 6.167
Authors: Gang Zhang; Dongwei Guo; Prasanta K Dash; Mariluz Araínga; Jayme L Wiederin; Nicole A Haverland; Jaclyn Knibbe-Hollinger; Andrea Martinez-Skinner; Pawel Ciborowski; Val S Goodfellow; Tadeusz A Wysocki; Beata J Wysocki; Larisa Y Poluektova; Xin-Ming Liu; JoEllyn M McMillan; Santhi Gorantla; Harris A Gelbard; Howard E Gendelman Journal: Nanomedicine Date: 2015-10-22 Impact factor: 5.307
Authors: Magdalene Ameka; Michael P Kahle; Mathew Perez-Neut; Saverio Gentile; Ahmed A Mirza; Bruce D Cuevas Journal: Biochem J Date: 2014-11-15 Impact factor: 3.857
Authors: Kyoko Tomita; Rohit Kohli; Brittany L MacLaurin; Petra Hirsova; Qianqian Guo; Luz H Gutierrez Sanchez; Harris A Gelbard; Burns C Blaxall; Samar H Ibrahim Journal: JCI Insight Date: 2017-08-03
Authors: Lisa R Trump; Ramesh C Nayak; Abhishek K Singh; Sana Emberesh; Ashley M Wellendorf; Carolyn M Lutzko; Jose A Cancelas Journal: Stem Cells Transl Med Date: 2019-02-21 Impact factor: 6.940
Authors: Igor A Schepetkin; Gulmira Özek; Temel Özek; Liliya N Kirpotina; Andrei I Khlebnikov; Mark T Quinn Journal: Molecules Date: 2021-06-15 Impact factor: 4.411
Authors: Tomomi Kiyota; Jatin Machhi; Yaman Lu; Bhagyalaxmi Dyavarshetty; Maryam Nemati; Gang Zhang; R Lee Mosley; Harris A Gelbard; Howard E Gendelman Journal: J Neuroinflammation Date: 2018-05-05 Impact factor: 8.322